ResMed Statistics
Total Valuation
ResMed has a market cap or net worth of $30.15 billion. The enterprise value is $29.34 billion.
| Market Cap | 30.15B |
| Enterprise Value | 29.34B |
Important Dates
The last earnings date was Thursday, April 30, 2026, after market close.
| Earnings Date | Apr 30, 2026 |
| Ex-Dividend Date | May 14, 2026 |
Share Statistics
ResMed has 145.06 million shares outstanding. The number of shares has decreased by -0.62% in one year.
| Current Share Class | 145.06M |
| Shares Outstanding | 145.06M |
| Shares Change (YoY) | -0.62% |
| Shares Change (QoQ) | -0.44% |
| Owned by Insiders (%) | 0.52% |
| Owned by Institutions (%) | 76.21% |
| Float | 144.17M |
Valuation Ratios
The trailing PE ratio is 20.05 and the forward PE ratio is 17.43. ResMed's PEG ratio is 1.24.
| PE Ratio | 20.05 |
| Forward PE | 17.43 |
| PS Ratio | 5.45 |
| Forward PS | n/a |
| PB Ratio | 4.64 |
| P/TBV Ratio | 9.97 |
| P/FCF Ratio | 17.19 |
| P/OCF Ratio | 15.95 |
| PEG Ratio | 1.24 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.84, with an EV/FCF ratio of 16.72.
| EV / Earnings | 19.31 |
| EV / Sales | 5.30 |
| EV / EBITDA | 13.84 |
| EV / EBIT | 15.24 |
| EV / FCF | 16.72 |
Financial Position
The company has a current ratio of 3.01, with a Debt / Equity ratio of 0.13.
| Current Ratio | 3.01 |
| Quick Ratio | 2.00 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | 0.39 |
| Debt / FCF | 0.48 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 25.25% and return on invested capital (ROIC) is 26.90%.
| Return on Equity (ROE) | 25.25% |
| Return on Assets (ROA) | 14.72% |
| Return on Invested Capital (ROIC) | 26.90% |
| Return on Capital Employed (ROCE) | 25.90% |
| Weighted Average Cost of Capital (WACC) | 8.65% |
| Revenue Per Employee | $554,889 |
| Profits Per Employee | $152,261 |
| Employee Count | 9,980 |
| Asset Turnover | 0.68 |
| Inventory Turnover | 2.24 |
Taxes
In the past 12 months, ResMed has paid $383.74 million in taxes.
| Income Tax | 383.74M |
| Effective Tax Rate | 20.16% |
Stock Price Statistics
The stock price has decreased by -13.37% in the last 52 weeks. The beta is 0.84, so ResMed's price volatility has been lower than the market average.
| Beta (5Y) | 0.84 |
| 52-Week Price Change | -13.37% |
| 50-Day Moving Average | 230.86 |
| 200-Day Moving Average | 255.25 |
| Relative Strength Index (RSI) | 32.71 |
| Average Volume (20 Days) | 1,313,037 |
Short Selling Information
The latest short interest is 11.49 million, so 7.92% of the outstanding shares have been sold short.
| Short Interest | 11.49M |
| Short Previous Month | 11.85M |
| Short % of Shares Out | 7.92% |
| Short % of Float | 7.97% |
| Short Ratio (days to cover) | 11.56 |
Income Statement
In the last 12 months, ResMed had revenue of $5.54 billion and earned $1.52 billion in profits. Earnings per share was $10.37.
| Revenue | 5.54B |
| Gross Profit | 3.44B |
| Operating Income | 1.92B |
| Pretax Income | 1.90B |
| Net Income | 1.52B |
| EBITDA | 2.12B |
| EBIT | 1.92B |
| Earnings Per Share (EPS) | $10.37 |
Balance Sheet
The company has $1.66 billion in cash and $843.17 million in debt, with a net cash position of $817.34 million or $5.63 per share.
| Cash & Cash Equivalents | 1.66B |
| Total Debt | 843.17M |
| Net Cash | 817.34M |
| Net Cash Per Share | $5.63 |
| Equity (Book Value) | 6.49B |
| Book Value Per Share | 44.76 |
| Working Capital | 2.71B |
Cash Flow
In the last 12 months, operating cash flow was $1.89 billion and capital expenditures -$135.74 million, giving a free cash flow of $1.75 billion.
| Operating Cash Flow | 1.89B |
| Capital Expenditures | -135.74M |
| Depreciation & Amortization | 194.62M |
| Net Borrowing | -10.00M |
| Free Cash Flow | 1.75B |
| FCF Per Share | $12.09 |
Margins
Gross margin is 62.18%, with operating and profit margins of 34.76% and 27.44%.
| Gross Margin | 62.18% |
| Operating Margin | 34.76% |
| Pretax Margin | 34.37% |
| Profit Margin | 27.44% |
| EBITDA Margin | 38.27% |
| EBIT Margin | 34.76% |
| FCF Margin | 31.68% |
Dividends & Yields
This stock pays an annual dividend of $2.40, which amounts to a dividend yield of 1.15%.
| Dividend Per Share | $2.40 |
| Dividend Yield | 1.15% |
| Dividend Growth (YoY) | 13.21% |
| Years of Dividend Growth | 14 |
| Payout Ratio | 23.14% |
| Buyback Yield | 0.62% |
| Shareholder Yield | 1.78% |
| Earnings Yield | 5.04% |
| FCF Yield | 5.82% |
Analyst Forecast
The average price target for ResMed is $288.56, which is 38.81% higher than the current price. The consensus rating is "Buy".
| Price Target | $288.56 |
| Price Target Difference | 38.81% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 8.52% |
| EPS Growth Forecast (5Y) | 10.86% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on August 31, 2010. It was a forward split with a ratio of 2:1.
| Last Split Date | Aug 31, 2010 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
ResMed has an Altman Z-Score of 12.56 and a Piotroski F-Score of 6.
| Altman Z-Score | 12.56 |
| Piotroski F-Score | 6 |